Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANGO AngioDynamics	$9.82 -9.6%	$10.22	$5.47 ▼ $13.50	$397.38M	0.56	577,804 shs	1.17 million shs
ATEC Alphatec	$10.21 -2.3%	$10.76	$4.88 ▼ $14.54	$1.47B	1.39	1.98 million shs	4.08 million shs
OFIX Orthofix Medical	$15.54 -4.7%	$17.45	$12.08 ▼ $20.73	$606.40M	1.06	256,538 shs	267,623 shs
SRDX Surmodics	$30.11 -2.1%	$32.34	$25.17 ▼ $42.44	$430.45M	1.19	278,253 shs	180,992 shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANGO AngioDynamics	-9.58%	-0.10%	+4.36%	+8.15%	+61.51%
ATEC Alphatec	-2.30%	+1.59%	-12.96%	+8.96%	-24.37%
OFIX Orthofix Medical	-4.66%	-3.84%	-8.64%	-10.43%	+12.12%
SRDX Surmodics	-2.11%	-1.63%	-1.25%	-23.81%	+11.68%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANGO AngioDynamics	4.229 of 5 stars	3.5	4.0	4.2	1.9	2.5	0.6
ATEC Alphatec	3.9994 of 5 stars	3.4	1.0	3.3	2.7	4.2	0.6
OFIX Orthofix Medical	2.5321 of 5 stars	3.4	3.0	0.0	0.8	2.5	1.3
SRDX Surmodics	4.1863 of 5 stars	3.1	3.0	3.4	2.9	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANGO AngioDynamics	3.00	Buy	$13.00	32.38% Upside
ATEC Alphatec	2.89	Moderate Buy	$17.67	73.03% Upside
OFIX Orthofix Medical	2.80	Moderate Buy	$23.33	50.15% Upside
SRDX Surmodics	2.25	Hold	$50.00	66.06% Upside

Current Analyst Ratings Breakdown

Latest ANGO, ATEC, OFIX, and SRDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/7/2025	SRDX Surmodics	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$43.00 ➝ $43.00
2/27/2025	ATEC Alphatec	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$12.00 ➝ $13.00
2/27/2025	ATEC Alphatec	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
2/26/2025	OFIX Orthofix Medical	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $24.00
2/26/2025	OFIX Orthofix Medical	Roth Mkm Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $22.00
1/30/2025	SRDX Surmodics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
1/22/2025	ATEC Alphatec	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$20.00 ➝ $21.00
1/22/2025	OFIX Orthofix Medical	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$24.00
1/14/2025	ATEC Alphatec	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
1/13/2025	ATEC Alphatec	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $16.00
1/10/2025	ANGO AngioDynamics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$14.00 ➝ $15.00

(Data available from 4/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANGO AngioDynamics	$286.50M	1.39	$4.07 per share	2.41	$5.13 per share	1.91
ATEC Alphatec	$611.56M	2.41	N/A	N/A	$0.57 per share	17.91
OFIX Orthofix Medical	$799.49M	0.76	N/A	N/A	$16.11 per share	0.96
SRDX Surmodics	$125.45M	3.43	$0.27 per share	111.12	$7.82 per share	3.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANGO AngioDynamics	-$184.35M	-$5.63	N/A	N/A	N/A	-79.38%	-7.26%	-4.78%	N/A
ATEC Alphatec	-$186.64M	-$1.14	N/A	N/A	N/A	-31.06%	-541.39%	-22.99%	5/6/2025 (Estimated)
OFIX Orthofix Medical	-$151.40M	-$3.29	N/A	N/A	N/A	-15.18%	-21.25%	-13.29%	5/6/2025 (Estimated)
SRDX Surmodics	-$11.54M	-$1.01	N/A	37.64	N/A	-11.48%	-4.39%	-2.95%	4/29/2025 (Estimated)

Latest ANGO, ATEC, OFIX, and SRDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/2/2025	Q3 2025	ANGO AngioDynamics	-$0.13	$0.03	+$0.16	-$0.11	$70.30 million	$72.00 million
2/26/2025	Q4 2024	ATEC Alphatec	-$0.19	-$0.23	-$0.04	-$0.23	$172.74 million	$176.79 million
2/6/2025	Q1 2025	SRDX Surmodics	-$0.08	-$0.04	+$0.04	-$0.26	$33.37 million	N/A
1/8/2025	Q2 25	ANGO AngioDynamics	-$0.11	-$0.04	+$0.07	-$0.26	$70.93 million	$72.90 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANGO AngioDynamics	N/A	N/A	N/A	N/A	N/A
ATEC Alphatec	N/A	N/A	N/A	N/A	N/A
OFIX Orthofix Medical	N/A	N/A	N/A	N/A	N/A
SRDX Surmodics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANGO AngioDynamics	N/A	1.98	1.24
ATEC Alphatec	30.21	2.32	1.15
OFIX Orthofix Medical	0.25	2.39	1.11
SRDX Surmodics	0.26	5.45	4.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANGO AngioDynamics	89.43%
ATEC Alphatec	66.35%
OFIX Orthofix Medical	89.76%
SRDX Surmodics	96.63%

Insider Ownership

Company	Insider Ownership
ANGO AngioDynamics	5.40%
ATEC Alphatec	22.80%
OFIX Orthofix Medical	2.60%
SRDX Surmodics	8.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANGO AngioDynamics	760	40.47 million	38.28 million	Optionable
ATEC Alphatec	700	144.15 million	109.48 million	Optionable
OFIX Orthofix Medical	1,090	39.02 million	37.22 million	Optionable
SRDX Surmodics	450	14.30 million	13.02 million	Optionable

ANGO, ATEC, OFIX, and SRDX Headlines

Recent News About These Companies

Surmodics Begins Full Commercial Release of Pounce XL Thrombectomy System

April 3 at 3:23 PM | evtoday.com

Surmodics launches Pounce XL thrombectomy system

April 3 at 9:49 AM | massdevice.com

Surmodics Announces Commercial Release of Pounce™ XL Thrombectomy System, Enabling Rapid Non-Surgical Clot Removal in Iliac and Femoral Arteries

April 3 at 9:49 AM | finance.yahoo.com

Surmodics, Inc. (NASDAQ:SRDX) Shares Purchased by Diametric Capital LP

April 2 at 6:19 AM | marketbeat.com

SurModics (SRDX) Gets a Hold from Barrington

March 31, 2025 | markets.businessinsider.com

Gardner Lewis Asset Management L P Purchases 49,944 Shares of Surmodics, Inc. (NASDAQ:SRDX)

March 29, 2025 | marketbeat.com

Boussard & Gavaudan Investment Management LLP Purchases New Shares in Surmodics, Inc. (NASDAQ:SRDX)

March 29, 2025 | marketbeat.com

38,043 Shares in Surmodics, Inc. (NASDAQ:SRDX) Bought by Mint Tower Capital Management B.V.

March 28, 2025 | marketbeat.com

Surmodics, Inc. (NASDAQ:SRDX) Shares Acquired by Commonwealth of Pennsylvania Public School Empls Retrmt SYS

March 27, 2025 | marketbeat.com

Zacks Research Decreases Earnings Estimates for Surmodics

March 24, 2025 | marketbeat.com

Royce & Associates LP Trims Stock Position in Surmodics, Inc. (NASDAQ:SRDX)

March 22, 2025 | marketbeat.com

Here's Why You Should Retain Surmodics Stock in Your Portfolio Now

March 18, 2025 | zacks.com

Surmodics, Inc. (NASDAQ:SRDX) Short Interest Update

March 16, 2025 | marketbeat.com

GTCR / Surmodics: Four Key Takeaways for M&A Antitrust from the First FTC Merger Challenge Under Trump

March 12, 2025 | jdsupra.com

Lake Street Upgrades Surmodics (SRDX)

March 8, 2025 | msn.com

Lake Street Capital Upgrades Surmodics (NASDAQ:SRDX) to "Buy"

March 8, 2025 | marketbeat.com

Surmodics says it will defend proposed acquisition by GTCR against FTC lawsuit

March 7, 2025 | pehub.com

FTC sues to block Surmodics acquisition by private equity over device coating competition

March 7, 2025 | fiercebiotech.com

SRDX Stock Falls Following Plan for Legal Action Against FTC Challenge

March 7, 2025 | zacks.com

FTC sues to block GTCR’s $627M Surmodics acquisition

March 7, 2025 | modernhealthcare.com

FTC challenges private equity firm’s acquisition of Surmodics

March 7, 2025 | massdevice.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANGO, ATEC, OFIX, and SRDX Company Descriptions

AngioDynamics NASDAQ:ANGO

$9.82 -1.04 (-9.58%)

Closing price 04/3/2025 04:00 PM Eastern

Extended Trading

$12.00 +2.18 (+22.19%)

As of 04:02 AM Eastern

AngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit, indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. The company also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. In addition, it provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. The company was founded in 1988 and is headquartered in Latham, New York.

Alphatec NASDAQ:ATEC

$10.21 -0.24 (-2.30%)

Closing price 04/3/2025 04:00 PM Eastern

Extended Trading

$10.33 +0.12 (+1.18%)

As of 05:36 AM Eastern

Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec surface modifications, Calibrate PSX, and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold for ease of handling and better endplate-to-endplate contact; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissues; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.

Orthofix Medical NASDAQ:OFIX

$15.54 -0.76 (-4.66%)

Closing price 04/3/2025 04:00 PM Eastern

Extended Trading

$13.27 -2.27 (-14.61%)

As of 05:34 AM Eastern

Orthofix Medical Inc. operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions. This segment also designs, develops, and markets a portfolio of navigation technologies, including tracked surgical tools, intelligent software, and imaging equipment based on machine-vision and optical innovations. The Global Orthopedics segment offers products and solutions that allow physicians to treat various orthopedic conditions related to limb reconstruction and deformity correction unrelated to the spine. This segment designs, develops, and markets external and internal fixation orthopedic products that are coupled with enabling digital technologies to serve the complete patient treatment pathway. It sells its products through distributors and sales representatives to hospitals, healthcare organizations, and healthcare providers. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.

Surmodics NASDAQ:SRDX

$30.11 -0.65 (-2.11%)

Closing price 04/3/2025 04:00 PM Eastern

Extended Trading

$30.10 -0.01 (-0.03%)

As of 04:15 AM Eastern

Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time